Stocktoria
WuXi AppTec Co., Ltd. 603259.SS
WuXi AppTec Co., Ltd. (603259.SS) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.33% (safety: safe). FY2025 revenue was CN¥45.5B at a 42.1% net margin.
About WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
How it ranks in Healthcare · percentile among 73 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.412 |
| Retained earnings / assets | 0.448 |
| EBIT / assets | 0.165 |
| Equity / liabilities | 3.485 |
FAQ
Is 603259.SS financially healthy?
WuXi AppTec Co., Ltd.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does 603259.SS pay a dividend, and is it safe?
Yes. WuXi AppTec Co., Ltd. pays a dividend yielding about 1.33% with a 25.9% payout ratio, rated “safe” for safety.
How profitable is 603259.SS?
In FY2025, WuXi AppTec Co., Ltd. had a net margin of 42.1% and a return on equity of 24.0%.
Computed from company filings · CN · as of 2025-12-31. Figures in CNY. Facts plus Stocktoria's own computed scores — not investment advice.